Overcoming the Challenges to HCV Elimination Among Individuals Who Are Incarcerated

HCV Elimination 2019 Program Image
This interactive video module provides in-depth expert analysis of the barriers impeding expanded diagnosis, treatment, and cure of HCV infection among individuals who are incarcerated in jails or prisons along with important insights on critical strategies needed to overcome these challenges.
Mark S. Sulkowski, MD
Program Director
Matthew J. Akiyama, MD, MSc
Debra Newman, PA-C, MPAS, MPH
Anne Spaulding, MD, MPH
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: June 6, 2019 Expiration: June 5, 2020
Multimedia Overcoming the Challenges to HCV Elimination Among Individuals Who Are Incarcerated
This program is divided into short segments. After reviewing all segments, click the Claim Credit button to complete the CME posttest and evaluation.
Introduction (3 mins)
See an overview of the activity and meet the expert faculty.
Launch Introduction (3 mins)
Burden of HCV Among Incarcerated Populations (10 mins)
Gain an understanding of the high burden of HCV infection among individuals who spend time in corrections facilities, the concept of churn between the community and jail system, and why screening and treating HCV infection among people who are incarcerated is essential to achieving HCV elimination in the United States.
Launch Burden of HCV Among Incarcerated Populations (10 mins)
Case 1, Part 1: HCV Screening Upon Entry Into Jail (11 mins)
Watch an important discussion on recommendations for HCV screening in jails, barriers impeding widespread adherence to those recommendations, and strategies for working toward overcoming the barriers.
Launch Case 1, Part 1: HCV Screening Upon Entry Into Jail (11 mins)
Case 1, Part 2: HCV Diagnosed Upon Entry Into Jail (23 mins)
Consider the substantial challenges associated with linkage to HCV care for persons who are diagnosed with HCV infection within the jail system and examine studies evaluating interventions aimed at addressing these challenges and increasing the proportion of diagnosed patients who are promptly linked to care within the community after release from jail.
Launch Case 1, Part 2: HCV Diagnosed Upon Entry Into Jail (23 mins)
Case 2: Incarceration During HCV Treatment (16 mins)
Find out why it is critical that jails and prisons have systems in place to provide a health condition and current medication assessment upon intake for all individuals so that medications can be continued without interruption.
Launch Case 2: Incarceration During HCV Treatment (16 mins)
Case 3: HCV Treatment in Prison (15 mins)
Review the status of HCV treatment in US prisons and learn about several approaches providers have been taking to try to expand treatment coverage in prisons.
Launch Case 3: HCV Treatment in Prison (15 mins)

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Incorporate available data on the burden of HCV among incarcerated populations and important demographic disparities in risk of incarceration when considering effective approaches to eliminating HCV in the United States
  • Apply strategies to expand HCV screening and diagnosis for people who are incarcerated or who have a history of incarceration
  • Advocate for interventions and policies that support HCV elimination efforts for people who are incarcerated

Acknowledgements

Jointly provided by

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

Endorsed by
This activity is supported by independent educational grants from
AbbVie
Gilead Sciences

Information on this Educational Activity

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Mark S. Sulkowski, MD

Professor of Medicine
Medical Director,
Viral Hepatitis Center
Divisions of Infectious Diseases and Gastroenterology/Hepatology
Johns Hopkins University School of Medicine
Baltimore, Maryland

Mark S. Sulkowski, MD, has disclosed that he has received consulting fees from AbbVie, Gilead Sciences, and Merck & Co, Inc, and funds for research support (paid to Johns Hopkins University) from AbbVie, Assembly Bio, Gilead Sciences, and Proteus Digital Health.

Faculty

Matthew J. Akiyama, MD, MSc

Assistant Professor of Medicine
Divisions of General Internal Medicine & Infectious Diseases
Department of Medicine
Albert Einstein College of Medicine & Montefiore Medical Center
Bronx, New York

Matthew J. Akiyama, MD, MSc, has no real or apparent conflicts of interest to report.
Debra Newman, PA-C, MPAS, MPH

Physician Assistant
Addiction Medicine & Psychiatry
First Judicial District Court/Adult Drug Court
Santa Fe, New Mexico

Debra Newman, PA-C, MPAS, MPH, has no real or apparent conflicts of interest to report.
Anne Spaulding, MD, MPH

Associate Professor
Department of Epidemiology
Rollins School of Public Health
Emory University
Infectious Disease Physician
Division of Infectious Disease
Department of Medicine
Emory School of Medicine
Atlanta, Georgia

Anne Spaulding, MD, MPH, has disclosed that she has received consulting fees from AbbVie and funds for research support from Gilead Sciences (paid to Emory University).

Staff

Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer M. Blanchette, PhD, has no real or apparent conflicts of interest to report.
Jenny Schulz, PhD

Director, Scientific Services

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

The PIM planners and managers have nothing to disclose.

The ASAM planners and managers have nothing to disclose.

The INHSU planners and managers have nothing to disclose.

The HealthHCV planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, registered nurses, pharmacists, and other healthcare providers involved in the screening, diagnosis, and treatment of patients infected with or at elevated risk of HCV.

Goal

The goal of this activity is to improve participants’ competence in implementing strategies to screen, diagnose, and cure diverse populations of individuals infected with HCV in the United States. 

Accreditation

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, American Society of Addiction Medicine, International Network for Hepatitis in Substance Users and HealthHCV.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Pharmacist Continuing Education

Credit Designation

Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008162-0000-19-852-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 06, 2019, through June 05, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Downloadable PDF resource from CCO on opioid use disorder treatment essentials for hepatologists and ID specialists managing HCV and/or HIV infection

Jenna Butner, MD Released: May 7, 2020

Latest data and best practice guidance on treating HCV in addiction medicine settings published by Clinical Care Options (CCO)

Andrew Seaman, MD Released: February 24, 2020

Expert commentary from CCO on how providers can act as advocates for increased access to HCV care for persons who use drugs and incarcerated individuals

Oluwaseun Falade-Nwulia, MBBS, MPH Released: December 18, 2019

Watch this video from a live symposium for expert guidance on approaches to improve diagnosis and treatment of HCV, HBV, and NASH.

Paul Y. Kwo, MD
Program Director
Manal F. Abdelmalek, MD, MPH Oluwaseun Falade-Nwulia, MBBS, MPH
Physicians: maximum of 1.5 AMA PRA Category 1 Credits US Physicians: maximum of 1.5 Medical Knowledge MOC point(s) Released: December 17, 2019 Expired: December 16, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?